- Home
- PSBD vs AMLX Comparison
PSBD vs AMLX Comparison
Compare PSBD & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- AMLX
- Stock Information
- Founded
- PSBD 2009
- AMLX 2014
- Country
- PSBD United States
- AMLX United States
- Employees
- PSBD N/A
- AMLX N/A
- Industry
- PSBD
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- AMLX Health Care
- Exchange
- PSBD Nasdaq
- AMLX Nasdaq
- Market Cap
- PSBD 524.9M
- AMLX 481.9M
- IPO Year
- PSBD 2024
- AMLX 2022
- Fundamental
- Price
- PSBD $15.69
- AMLX $4.76
- Analyst Decision
- PSBD Buy
- AMLX Buy
- Analyst Count
- PSBD 7
- AMLX 7
- Target Price
- PSBD $16.93
- AMLX $6.00
- AVG Volume (30 Days)
- PSBD 24.5K
- AMLX 1.7M
- Earning Date
- PSBD 11-05-2024
- AMLX 11-07-2024
- Dividend Yield
- PSBD 11.92%
- AMLX N/A
- EPS Growth
- PSBD N/A
- AMLX N/A
- EPS
- PSBD N/A
- AMLX N/A
- Revenue
- PSBD N/A
- AMLX $196,485,000.00
- Revenue This Year
- PSBD N/A
- AMLX N/A
- Revenue Next Year
- PSBD N/A
- AMLX $149.49
- P/E Ratio
- PSBD N/A
- AMLX N/A
- Revenue Growth
- PSBD N/A
- AMLX N/A
- 52 Week Low
- PSBD $15.27
- AMLX $1.58
- 52 Week High
- PSBD $17.12
- AMLX $19.95
- Technical
- Relative Strength Index (RSI)
- PSBD 37.99
- AMLX 45.23
- Support Level
- PSBD $15.63
- AMLX $4.88
- Resistance Level
- PSBD $16.07
- AMLX $7.27
- Average True Range (ATR)
- PSBD 0.22
- AMLX 0.59
- MACD
- PSBD -0.02
- AMLX -0.18
- Stochastic Oscillator
- PSBD 8.87
- AMLX 7.03
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.